<DOC>
	<DOCNO>NCT00911066</DOCNO>
	<brief_summary>An open-label , multicenter , phase 1 , dose escalation study MLN4924 adult patient acute myelogenous leukemia ( AML ) , high-grade myelodysplastic syndrome ( MDS ) . The patient population consist adult previously diagnose AML include high-grade MDS standard curative , life-prolonging treatment exist longer effective .</brief_summary>
	<brief_title>MLN4924 Treatment Acute Myelogenous Leukemia , Myelodysplastic Syndrome , Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age great equal 18 year Have follow diagnosis : AML ALL ( dose escalation phase ) include leukemia secondary prior chemotherapy result antecedent hematologic disorder , fail achieve complete response ( CR ) relapse prior therapy candidate potentially curative treatment . Acute Promyelocytic Leukemia ( APL ) patient eligible AML ALL patient age 60 receive prior therapy also eligible candidate standard induction chemotherapy Highgrade MDS , define &gt; 10 % blast bone marrow examination Lowgrade MDS , define &lt; 10 % blast bone marrow examination ( Schedule B expansion cohort ) Patients willing refrain donate blood least 90 day final dose MLN4924 ( male patient ) willing refrain donate semen least 4 month final dose MLN4924 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Female patient postmenopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse Male patient agree practice 2 effective method contraception abstain heterosexual intercourse Voluntary write consent Suitable venous access Adequate clinical laboratory value screen period specify protocol Patients hydroxyurea may include study may continue hydroxyurea participate study . Female patient lactate positive serum pregnancy test screen period Any serious medical psychiatric illness Treatment investigational product Systemic antineoplastic therapy radiotherapy within 14 day first dose study drug , except hydroxyurea Major surgery within 14 day first dose study drug Lifethreatening illness unrelated cancer Clinically uncontrolled central nervous system ( CNS ) involvement Known human immunodeficiency virus ( HIV ) positive Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection Evidence uncontrolled cardiovascular condition specify protocol Diarrhea &gt; Grade 1 , base NCI CTCAE categorization Systemic treatment prohibit medication Ongoing anticoagulant therapy ( eg , aspirin , Coumadin , heparin ) hold permit bone marrow sample Use acetaminophen , acetaminophencontaining product , statin permit day dosing , day dosing , day dose MLN4924</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>